Cyclohexylmethylboronic acid
Product Information
Molecular Formula
C7H15BO2
Molecular Weight
142.00
Description
Cyclohexylmethylboronic acid is a vital compound used in the biomedical industry. It is commonly employed in the synthesis of pharmaceutical drugs for the treatment of various diseases. This versatile product serves as a crucial building block in the development of novel medications targeting specific diseases.
Synonyms
Boronic acid, B-(cyclohexylmethyl)-; Boronic acid, (cyclohexylmethyl)-; (Cyclohexylmethyl)boronicacid; Cyclohexylmethylboronic acid
IUPAC Name
cyclohexylmethylboronic acid
SMILES
B(CC1CCCCC1)(O)O
InChI
InChI=1S/C7H15BO2/c9-8(10)6-7-4-2-1-3-5-7/h7,9-10H,1-6H2
InChI Key
STYXWXRMARWJRD-UHFFFAOYSA-N
Flash Point
Not applicable
Safety Information
Hazards
H315 - H318 - H335
Precautionary Statement
P261 - P280 - P305 + P351 + P338
Computed Properties
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
2
Rotatable Bond Count
2
Exact Mass
142.1165099 g/mol
Monoisotopic Mass
142.1165099 g/mol
Topological Polar Surface Area
40.5Ų
Heavy Atom Count
10
Formal Charge
0
Complexity
89.6
Isotope Atom Count
0
Defined Atom Stereocenter Count
0
Undefined Atom Stereocenter Count
0
Defined Bond Stereocenter Count
0
Undefined Bond Stereocenter Count
0
Covalently-Bonded Unit Count
1
Compound Is Canonicalized
Yes
Patents
| Publication Number | Title | Priority Date |
|---|---|---|
| JP-2022041072-A | Improved metallo-β-lactamase inhibitor | 2020-08-31 |
| JP-2022021687-A | Method for Producing N-Substituted (Meta) Acrylamide | 2020-07-22 |
| KR-20210039968-A | Bicyclic compound and use thereof | 2019-10-02 |
| US-2021101892-A1 | Bicyclic compound and use thereof | 2019-10-02 |
| WO-2021066578-A1 | Bicyclic compound and use thereof | 2019-10-02 |
| TW-202126632-A | Bicyclic compound and use thereof | 2019-10-02 |
| US-11111237-B2 | Bicyclic compound and use thereof | 2019-10-02 |
| DE-102017222072-A1 | Hydrogel with antioxidant action | 2017-12-06 |
| WO-2019079119-A1 | SULFONAMIDES AND ASSOCIATED COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | 2017-10-17 |
| CN-111417622-A | Sulfonamides and compositions thereof for the treatment of conditions associated with N L RP activity | 2017-10-17 |
